DMS released 9 months 18 sales which reached €16.9m (-12%), including a 15% fall in the historic Imaging business to €16.2m and an increase in Wellness and Biotech (from €0.4m to €0.7m).
As usual (see our comments for Q1 and H1 18), new segments are growing from a very low basis while the historic Imaging business is still decreasing, albeit at a slower pace in Q3 (-15% in 9 months vs -19% in H1). It is also worth noting that the comparison basis is getting easier (Q3 17 was actually down 6% and sales over 9 months in FY17 down 5%).
In Q3 18, new segments were up 51% (DMS Biotech) but again on a very small number (€0.5m so far this year and the simple rounding of small numbers does not allow us to confirm this is really +51%!), with DMS Wellness up to €0.2m from scratch.
We also note that the group has postponed the results initially expected in H2 for the first clinical studies of its arthrosis treatment solution to H1 19, which is not exactly good news. As a reminder, last full-year sales reached on a comparable perimeter €27.1m. In other words, it would take a strong €10m sales level in Q4 to reach flat sales.
This is unlikely, despite the fact a table for Egypt may be booked at last, as announced earlier. This suggests our numbers are probably (again) too high. No word either on the new factory (initially planned to be built before year-end 2018).
While the share price has been under strong pressure as of late, we believe the market will wait for better signs of a real pick-up in sales before having a closer look at the group.
On a fundamental basis, it does look cheap, but management has to convince it can really improve the momentum of sales and profits, which is not obvious at this stage.
The AlphaValue Corporate Services analysts are AlphaValue’s sector specialists. Their robust knowledge of the business models in their sectors enables the rapid generation of incisive, relevant research and advantageous interaction with the management teams.